Premium
P3‐012: Advancing Therapeutics for Neuroinflammation in Alzheimer's Disease: Clinical Development Considerations
Author(s) -
Margolin Richard A.,
Schneider Lon S.,
Cutter Gary R.,
Breitner John C.S.,
Doody Rachelle S.,
Landreth Gary,
Chain Daniel
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1669
Subject(s) - neuroinflammation , medicine , biomarker , clinical trial , disease , drug development , bioinformatics , population , neuropathology , drug , oncology , pharmacology , biology , biochemistry , environmental health
(AUC1⁄40.599 [OR1⁄41.038, c.i. 1.023-1.053]; p<0.0001) also discriminated between Ab+ and Abgroups, as did the ADASCog11 (AUC1⁄40.615, [OR1⁄41.088, c.i. 1.057-1.120]; p<0.0001). The screening measures also showed significant predictive utility; MMSE (AUC1⁄40.620, [OR1⁄40.784, c.i. 0.727-0.847]; p<0.0001), CDR-SB (AUC1⁄40.564, [OR1⁄41.215, c.i. 1.060-1.393]; p1⁄40.0053), and particularly the verbal episodic memory task FCSRT Free Recall (AUC1⁄40.671, [OR1⁄40.892, c.i. 0.870-0.915]; p<0.0001). Conclusions: Even following screening of subjects on the basis of cognitive test performance, cognitive test scores can help predict CSF Ab status in a prodromal AD population. Measures of visual and verbal episodic memory appear to be particularly useful. As some of these measures were administered following initial screening, further research to establish their performance as first line screening tools is warranted.